Tribute Pharmaceuticals Canada Inc. (TBUFF) 0.4779 $TBUFF
Tribute Pharmaceuticals Receives 4th Uracyst(R) Patent in United States
Marketwire - Thu Sep 25, 8:20AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, today announced that it has received an additional patent from the U.S. Patent and Trademark Office (USPTO) for intellectual property that is central to one of the Company's lead products, Uracyst(R) (a sterile sodium chondroitin sulfate solution, 2%, which is used in the treatment of interstitial cystitis / bladder pain syndrome ("IC/BPS" ).
Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results
Marketwire - Mon Aug 11, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and U.S., today announced financial results for its quarter ending June 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
Tribute Pharmaceuticals to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Monday, August 11, 2014
ACCESSWIRE - Fri Aug 08, 3:26PM CDT
MILTON, ONTARIO / ACCESSWIRE / August 8, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Monday, August 11, 2014 at 11:00 AM Eastern Time.
Tribute Pharmaceuticals Schedules Second Quarter 2014 Financial Results Conference Call
Marketwire - Wed Aug 06, 11:17AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Monday, August 11, 2014 at 11 AM EDT to review and discuss the Company's results for its second quarter ending June 30, 2014.
Tribute Pharmaceuticals Begins Trading on the OTCQX Marketplace
Marketwire - Tue Aug 05, 6:32AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its common shares will begin trading today on the OTCQX(R) marketplace under the symbol "TBUFF". Tribute's common shares will also continue to trade on the TSX Venture Exchange under the symbol "TRX".
Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Conference
Marketwire - Mon Jun 16, 7:03AM CDT
Tribute Pharmaceuticals Canada Inc. ("Tribute" or "the Company" (TSX VENTURE: TRX) (OTCQB: TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced today that its President and Chief Executive Officer, Rob Harris, will present an update on the Company and its corporate activities, at the Bloom Burton & Co. ("Bloom Burton" Annual Healthcare Investor Conference, to be held on Wednesday, June 18 at the Toronto Board of Trade.
Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth
Marketwire - Mon Mar 31, 6:03AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or the "Company" , a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced financial results for its fiscal year ending December 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency (unless otherwise noted) and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
CAMBIA(R) Update From Tribute Pharmaceuticals
Marketwire Canada - Fri Dec 20, 7:00AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) (OTCBB:TBUFF) (PINKSHEETS:TBUFF) ("Tribute" or the "Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today commented on the recent acquisition of CAMBIA(R) (diclofenac potassium for oral solution) by Depomed, Inc. (NASDAQ
EPO). Depomed, Inc. ("Depomed" announced earlier this week that it had acquired the United States and Canadian rights to CAMBIA(R) (diclofenac potassium for oral solution) from Nautilus Neurosciences, Inc. ("Nautilus" of Bedminster, NJ. For a complete copy of Depomed's recent press release please visit www.depomed.com.
OTC Daily Alert Stock Watch - Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)
WorldStockWire - Sat Sep 07, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Tribute Pharmaceuticals Announces Double Digit Growth in Second Quarter 2013
Marketwire - Fri Aug 09, 8:52AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 second quarter ending June 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
Tribute Pharmaceuticals Announces Double Digit Growth in First Quarter 2013
Marketwire - Tue May 14, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company" , a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 first quarter ending March 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth
Marketwire - Thu Mar 21, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF) ("Tribute" or "the Company" , a Canadian specialty pharmaceutical company, today announced financial results for the year ended December 31, 2012. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
Tribute Pharmaceuticals Receives 4th Uracyst(R) Patent in United States
Marketwire - Thu Sep 25, 8:20AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, today announced that it has received an additional patent from the U.S. Patent and Trademark Office (USPTO) for intellectual property that is central to one of the Company's lead products, Uracyst(R) (a sterile sodium chondroitin sulfate solution, 2%, which is used in the treatment of interstitial cystitis / bladder pain syndrome ("IC/BPS" ). Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results
Marketwire - Mon Aug 11, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and U.S., today announced financial results for its quarter ending June 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). Tribute Pharmaceuticals to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Monday, August 11, 2014
ACCESSWIRE - Fri Aug 08, 3:26PM CDT
MILTON, ONTARIO / ACCESSWIRE / August 8, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Monday, August 11, 2014 at 11:00 AM Eastern Time.
Tribute Pharmaceuticals Schedules Second Quarter 2014 Financial Results Conference Call
Marketwire - Wed Aug 06, 11:17AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Monday, August 11, 2014 at 11 AM EDT to review and discuss the Company's results for its second quarter ending June 30, 2014. Tribute Pharmaceuticals Begins Trading on the OTCQX Marketplace
Marketwire - Tue Aug 05, 6:32AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its common shares will begin trading today on the OTCQX(R) marketplace under the symbol "TBUFF". Tribute's common shares will also continue to trade on the TSX Venture Exchange under the symbol "TRX". Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Conference
Marketwire - Mon Jun 16, 7:03AM CDT
Tribute Pharmaceuticals Canada Inc. ("Tribute" or "the Company"
(TSX VENTURE: TRX) (OTCQB: TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced today that its President and Chief Executive Officer, Rob Harris, will present an update on the Company and its corporate activities, at the Bloom Burton & Co. ("Bloom Burton" Annual Healthcare Investor Conference, to be held on Wednesday, June 18 at the Toronto Board of Trade. Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth
Marketwire - Mon Mar 31, 6:03AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or the "Company"
, a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced financial results for its fiscal year ending December 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency (unless otherwise noted) and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). CAMBIA(R) Update From Tribute Pharmaceuticals
Marketwire Canada - Fri Dec 20, 7:00AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) (OTCBB:TBUFF) (PINKSHEETS:TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today commented on the recent acquisition of CAMBIA(R) (diclofenac potassium for oral solution) by Depomed, Inc. (NASDAQ EPO). Depomed, Inc. ("Depomed" announced earlier this week that it had acquired the United States and Canadian rights to CAMBIA(R) (diclofenac potassium for oral solution) from Nautilus Neurosciences, Inc. ("Nautilus" of Bedminster, NJ. For a complete copy of Depomed's recent press release please visit www.depomed.com. OTC Daily Alert Stock Watch - Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)
WorldStockWire - Sat Sep 07, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Tribute Pharmaceuticals Announces Double Digit Growth in Second Quarter 2013
Marketwire - Fri Aug 09, 8:52AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 second quarter ending June 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). Tribute Pharmaceuticals Announces Double Digit Growth in First Quarter 2013
Marketwire - Tue May 14, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 first quarter ending March 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth
Marketwire - Thu Mar 21, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF) ("Tribute" or "the Company"
, a Canadian specialty pharmaceutical company, today announced financial results for the year ended December 31, 2012. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). 
